Tumor tissue and tumor-associated vasculature

Tumor tissue and tumor-associated vasculature constitute a specialized compartment of the tumor microenvironment essential for the survival and progression of solid tumors. The vasculature within tumors is distinct from normal blood vessels, often being leaky, dilated, and haphazardly organized due to an imbalance of pro- and anti-angiogenic factors (National Cancer Institute, 2018). This abnormal structure facilitates high interstitial fluid pressure and impairs the delivery of chemotherapeutic agents while promoting metastatic dissemination (Jain, R. K., Science, 2005). Therapeutic interventions targeting this system generally fall into two categories: anti-angiogenic therapies that block the signaling required for new vessel growth and vascular disrupting agents (VDAs) that target the established cytoskeleton of tumor endothelial cells to induce vascular collapse (Thorpe, P. E., Clinical Cancer Research, 2004). While these strategies have shown efficacy in reducing tumor burden, they are often associated with significant side effects such as hypertension and bleeding, and tumors frequently develop resistance through alternative growth pathways (Kerbel, R. S., NEJM, 2008). Understanding the dynamic interaction between tumor cells and their blood supply remains a cornerstone of modern oncology and drug development.

Other names

Tumor microenvironmentTumor neovasculatureTumor stromaAngiogenic vessels

Drugs targeting this system work by either inhibiting angiogenesis or disrupting existing vessels. Anti-angiogenic agents (e.g., Bevacizumab) bind to VEGF or its receptors to prevent the signaling that triggers new blood vessel growth (National Cancer Institute). Vascular disrupting agents (VDAs) (e.g., Combretastatin) target the tubulin cytoskeleton of endothelial cells in established tumor vessels, causing them to collapse and leading to secondary tumor cell death due to ischemia (Thorpe, P. E., Clinical Cancer Research, 2004).